Atea Pharmaceuticals Presents New Modeling Data for Hepatitis C Treatment Regimen.

Atea Pharmaceuticals presented modeling data predicting its combination regimen of bemnifosbuvir and ruzasvir achieved near-complete inhibition of viral replication and assembly, with a modeled time to cure of approximately 7-8 weeks. The findings support the fixed-dose combination regimen as a potential best-in-class, short-duration treatment of hepatitis C virus, further validating the company's Phase 2 study results.